E-LIB Suche - Ergebnisse für: SCHLINGENSIEPEN, K

1

8714 Trabedersen (AP 12009) in recurrent or refractory high..:

Bogdahn, U. ; Mahapatra, A.K. ; Suri, A....
European Journal of Cancer Supplements. 7 (2009) 2 - p. 497-498 , 2009

2

Targeted tumor therapy with the TGF-β2 antisense compound A..:

SCHLINGENSIEPEN, K ; SCHLINGENSIEPEN, R ; STEINBRECHER, A...
Cytokine & Growth Factor Reviews. 17 (2006) 1-2 - p. 129-139 , 2006

Link: https://doi.org/10.1016/..

3

450 The TGF-beta1 antisense oligonucleotide AP 11014 for th..:

Schlingensiepen, K. ; Bischof, A. ; Egger, T....
European Journal of Cancer Supplements. 2 (2004) 8 - p. 134 , 2004

Link: https://doi.org/10.1016/..

4

449 Treatment of pancreatic cancer by TGF-beta2 suppression..:

Stauder, G. ; Bischof, A. ; Egger, T....
European Journal of Cancer Supplements. 2 (2004) 8 - p. 134 , 2004

Link: https://doi.org/10.1016/..

5

439 TGF-beta2 suppression by the antisense oligonucleotide ..:

Schlingensiepen, K. ; Hau, P. ; Brawanski, A....
European Journal of Cancer Supplements. 2 (2004) 8 - p. 131-132 , 2004

Link: https://doi.org/10.1016/..

6

359 Effect of the TGF-beta 2 specific antisense oligodeoxyn..:

Jaschinski, F. ; Kielmanowicz, M. ; Rothhammer, T...
European Journal of Cancer Supplements. 8 (2010) 7 - p. 113-114 , 2010

Link: https://doi.org/10.1016/..

7

530 Activity of the TGF-beta 2 specific antisense oligodeox..:

Jaschinski, F. ; Lang, S.A. ; Moser, C....
European Journal of Cancer Supplements. 8 (2010) 7 - p. 169 , 2010

Link: https://doi.org/10.1016/..

8

Targeted therapy for high-grade glioma with the TGF- 2 inhi..:

Bogdahn, U. ; Hau, P. ; Stockhammer, G....
Neuro-Oncology. 13 (2010) 1 - p. 132-142 , 2010

Link: https://doi.org/10.1093/..

9

1259 Trabedersen (AP 12009) in the treatment of pancreatic ..:

Oettle, H. ; Hilbig, A. ; Seufferlein, T....
European Journal of Cancer Supplements. 7 (2009) 2 - p. 138 , 2009

Link: https://doi.org/10.1016/..

10

329 POSTER A phase llb study in patients with recurrent mal..:

Bogdahn, U. ; Zaaroor, M. ; Parfenov, V....
European Journal of Cancer Supplements. 4 (2006) 12 - p. 103 , 2006

Link: https://doi.org/10.1016/..

11

820 TGF-beta1 suppression by the antisense oligonucleotide ..:

Jachimczak, P. ; Schlingensiepen, K.-H. ; Schlingensiepen, R....
European Journal of Cancer Supplements. 1 (2003) 5 - p. S246 , 2003

Link: https://doi.org/10.1016/..

12

34 The TGF-beta2 antisense ollgonucleotide ap 12009 as a th..:

Hau, P. ; Bogdahn, U. ; Schlaier, J....
European Journal of Cancer Supplements. 1 (2003) 5 - p. S14 , 2003

Link: https://doi.org/10.1016/..

13

Reduction of erbB2 Gene-Product in Mamma Carcinoma Cell Lin..:

Bertram, J. ; Killian, M. ; Brysch, W...
Biochemical and Biophysical Research Communications. 200 (1994) 1 - p. 661-667 , 1994

Link: https://doi.org/10.1006/..

14

Autoinduction of Platelet Derived Growth Factor (PDGF) A-Ch..:

Behl, C. ; Bogdahn, U. ; Winkler, J....
Biochemical and Biophysical Research Communications. 193 (1993) 2 - p. 744-751 , 1993

Link: https://doi.org/10.1006/..

15

Inhibition of bFGF and several IEG's by antisense oligodeox..:

Gerdes, W. ; Schlingensiepen, K.H. ; Brysch, W..
Neurochemistry International. 21 (1992) - p. A7 , 1992

Link: https://doi.org/10.1016/..